secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-02-11T23:59:59+00:00
Accession:  0001193805-22-000265
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus CMO Steve Hughes steps down; Kelly Lindert named Chief Development Officer, Vaccines
--------------------------------------------------------------------------------

- Dr. Steve Hughes resigns as CMO effective Feb 14, 2022, to become Strategic Clinical Advisor.
- Dr. Kelly Lindert, formerly SVP and Head of Vaccines, appointed Chief Development Officer, Vaccines.
- Hughes will continue supporting Arcturus programs in an advisory capacity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522000265/0001193805-22-000265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522000265/e621318_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-000265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer